Lei Zhang

Lei Zhang

Auto-generated profile, based on publicly available information

Lei Zhang

Department of Pharmacology and Pharmaceutical Sciences, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, USA

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
24 October 2022 in Theranostics
Verified
Journal Article
Open access
PDF file
TCTao Chen
Tao Chen
ZYZhiqing Yuan
Zhiqing Yuan
ZLZhou Lei
Zhou Lei
JDJinlin Duan
Jinlin Duan
JXJunyan Xue
Junyan Xue
YZYonglong Zhang
Yonglong Zhang
Rationale: Hepatocellular carcinoma (HCC) is one of the most severe cancers worldwide, with few effective targeted therapies for HCC. Lipid metabolic reprogramming is emerged as a hallmark of cancer metabolism that guides response to antitumoral therapies. Such lipid metabolic alteration in cancers is critically regulated by the mammalian target of rapamycin mTOR, which is considered as a promising therapeutic target. Despite efforts, mTOR inhibitors (mTORi) have produced limited response clinically, partly due to incomplete knowledge of mTORC1 addiction in cancers.

19 December 2025 in Nature Communications
Verified
Journal Article
Open access
PDF file
LZLei Zhang
Lei Zhang
SSSrinivasarao Singireddi
Srinivasarao Singireddi
AAArshad J. Ansari
Arshad J. Ansari
GKGuoyun Kao
Guoyun Kao
SKSunny H. Kim
Sunny H. Kim
YZYong Zhang
Yong Zhang
Cell-secreted exosomes have been emerging as an increasingly attractive form of nanomaterials for biomedical research. Various approaches have been established to genetically modify exosomes with proteins of interest for new and/or improved functions. However, equipping exosomes with diverse non-protein biomolecules remains largely dependent on random chemical conjugation or membrane insertion, hindering the application potential of exosomes. Herein, we develop a technology for site-specific functionalization of exosome with different synthetic groups by exploiting surface-expressed CD38, an ADP-ribosyl cyclase, and its covalent inhibitor derived from nicotinamide adenine dinucleotide (NAD + ). The designed ADP-ribosyl cyclase-enabled exosomes (ARC Exos) carrying conjugated fluorescent imaging probes, small-molecule ligands, cytotoxic payloads, and bone-targeting agents are demonstrated with in vitro and/or in vivo activities and specificities. This ARC Exos-based platform provides a general approach with great versatility for chemically reprogramming exosomes.

17 June 2025 in Biomedicine & Pharmacotherapy
Verified
Journal Article
Open access
LZLei Zhang
Lei Zhang
MAMashael F. Aldossari
Mashael F. Aldossari
AAArshad J. Ansari
Arshad J. Ansari
GKGuoyun Kao
Guoyun Kao
SKSunny H. Kim
Sunny H. Kim
YZYong Zhang
Yong Zhang
Antibody-drug conjugates (ADCs) bring superior efficacy and safety profiles to the clinic by harnessing the power of biologics and chemotherapy. Despite numerous ADCs at different preclinical and clinical stages, homogeneous ADC with increased numbers of payloads conjugated at specific positions are still desired for enhanced pharmacological properties. To generate site-specifically conjugated ADCs with greater drug-to-antibody ratios (DARs), monoclonal antibodies targeting prostate-specific membrane antigens (PSMA) were genetically fused with tandem CD38 enzymes, a member of the ADP-ribosyl cyclase family. The resulting antibody-CD38 fusions coupled with its dinucleotide substrate-derived drug linker facilitate generation of ADP-ribosyl cyclase-enable ADCs (ARC-ADCs) carrying 2, 4, 6, and 8 tubulin inhibitors. In vitro and in vivo studies indicated highly potent and selective cytotoxicity against human PSMA-expressing prostate cancer cells for the anti-PSMA ARC-ADC with a DAR of 6. This proof-of-concept study demonstrates feasibility of producing site-specific ARC-ADCs with increased DARs by tandemly fused CD38 and generates candidate ADCs for targeting prostate tumors.

23 October 2026 in Acta Biomaterialia
Verified
Journal Article
Closed access
GKGuoyun Kao
Guoyun Kao
LZLei Zhang
Lei Zhang
SKSunny H. Kim
Sunny H. Kim
QHQianyuan He
Qianyuan He
ZZZeyu Zhang
Zeyu Zhang
YZYong Zhang
Yong Zhang